新型乳腺癌靶向治疗药物帕博西尼的研究进展

Research progress of palbociclib:a novel targeted therapy drug for breast cancer

帕博西尼是一种口服、靶向性药物,对绝经后晚期或转移性雌激素受体阳性/HER-2阴性(ER^+/HER-2^-)乳腺癌患者具有良好的疗效。目前研究表明,帕博西尼与来曲唑联合用药相比单用来曲唑治疗,能延长患者无进展生存期。美国食品和药物管理局于2015年2月批准帕博西尼联合来曲唑用于绝经后晚期或转移性ER^+/HER-2^-乳腺癌的初始内分泌治疗。帕博西尼最常见的不良反应主要为中性粒细胞减少。

Palbociclib with estrogen receptor （ER） is an oral and targeted drug, which has a positive/human epidermal growth factor good effect on postmenopausal women receptor 2 （HER2） - negative （ ER ＋/ HER- 2-） advanced or metastatic breast cancer. Present study showed that compared with letrozole, the progression-free-survival （PFS） of palbociclib combined with letrozole was extended. In February 2015, the Food and Drug Administration （FDA） approved palbociclib combination with letrozole, as initial endocrine- based therapy for postmenopausal women with ER＋/HER-2- advanced or metastatic breast cancer. Neutropenia was the most common adverse reaction of palbociclib.